Antimicrobial resistance (AMR) in Klebsiellapneumoniae poses a significant global health threat, characterized by its resistance to critical antibiotics such as carbapenems and colistin. This bacterium is responsible for severe infections like pneumonia, sepsis, and meningitis, with mortality rates reaching 50% even with antibiotic treatment. The rise of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of K. pneumoniae is particularly alarming, notably in healthcare settings where it is a leading cause of hospital-acquired infections. In India, over 70% of K. pneumoniae isolates exhibit resistance to fluoroquinolones and third-generation cephalosporins, while 56.6% are resistant to carbapenems. K. pneumoniae has a remarkable ability to acquire resistance genes through horizontal gene transfer, facilitated by enzymes such as extended-spectrum β-lactamases (ESBLs) and carbapenemases. Often considered a harbinger of AMR trends, new resistance genes frequently emerge in K. pneumoniae before spreading to other Gram-negative pathogens. The COVID-19 pandemic has exacerbated this crisis, with high rates of resistance observed in K. pneumoniae isolates from ICU patients co-infected with SARS-CoV-2. Urgent measures are essential to develop novel antibiotic combinations for combating MDR K. pneumoniae infections, particularly while new antibiotics are under development.